Wei Wei Chen - 21 Jun 2023 Form 4 Insider Report for LianBio (LIANY)

Reporting relationship: Director
Issuer ticker: LIANY
Reported as of: 21 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2023, 16:23:09 UTC
Prior SEC filing: 08 Apr 2022
Source filing: View source filing
Reporting owner signature: By: /s/ Angela Chen, Attorney-in-Fact

Key filing fact

Wei Wei Chen filed Form 4 for LianBio (LIANY) on 23 Jun 2023.

Key facts

This page summarizes Wei Wei Chen's Form 4 filing for LianBio (LIANY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2023, 16:23.

Change

Previous filing in this sequence was filed on 08 Apr 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LIAN transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +36,300
Change %
Price: $0.000000
Shares after: 36,300
Date: 21 Jun 2023
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 36,300
Exercise price: $2.40
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date.